Skip to content
A Green Sign – Lifestyle
Author:
Mylan Inc.
Viatris Announces Multiple Data Presentations at the 2026 American Society of Cataract and Refractive Surgery Annual Meeting
April 10, 2026
Viatris Advances Innovative Portfolio with Approval of Effexor® in Japan for Adults with Generalized Anxiety Disorder (GAD)
March 23, 2026
Viatris to Outline its Vision for Sustained Revenue and Earnings Growth Through 2030
March 19, 2026
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
March 5, 2026
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
March 5, 2026
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
March 5, 2026
←
Previous Page
1
2